🧫 Adjuvant cretostimogene cuts recurrence after resection
🧫 Adjuvant cretostimogene cuts recurrence after resection
Adjuvant intravesical cretostimogene grenadenorepvec cut recurrence risk by 68% versus surveillance alone in the randomized Phase III PIVOT-006 trial of 367 patients with intermediate-risk and high-grade Ta ≤3 cm non-muscle–invasive bladder cancer after complete tumor resection. The top-line study readout showed a hazard ratio of 0.32 at a median 17 months' follow-up, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations.
Why It Matters To Oncology
NMIBC recurrence remains a major clinical problem after resection, driving repeat invasive procedures and ongoing disease burden.
CG Oncology estimates roughly 50,000 patients fall into this target population, which currently has no FDA-approved adjuvant treatment options.
The result expands cretostimogene's potential beyond BCG-unresponsive high-risk disease, where the company is already advancing a regulatory filing.
The Financials
CG Oncology shares rose about 14% Monday after the Phase III readout.
Morgan Stanley had framed the Street's efficacy bar around a hazard ratio near 0.6, versus a clinical bar near 0.7; PIVOT-006 came in well ahead at 0.32.
The company expects these data to support a second BLA in intermediate-risk and high-grade Ta NMIBC in Q2 2027.
What They're Saying
Chief Medical Officer Vijay Kasturi said reducing recurrence is meaningful because recurrence leads to additional invasive procedures and continued disease burden.
CEO Arthur Kuan called PIVOT-006 an opportunity to change clinical practice and said the results position cretostimogene as the first and only therapeutic candidate to show a significant recurrence benefit in a pivotal Phase III trial in this setting.
Investors and clinicians will likely focus on whether the strong recurrence-free survival signal translates into durable adoption in adjuvant NMIBC.
What's Next
Detailed PIVOT-006 data are scheduled for presentation at next month's Society of Urologic Oncology annual meeting.
CG also plans to broaden its first BLA in high-risk BCG-unresponsive NMIBC, after FDA feedback, to include high-grade papillary-only disease in addition to CIS with or without papillary tumors.
That initial submission is now expected by the end of March 2027, later than the prior Q4 2026 timeline.
Reference: CG Oncology's oncolytic virus cuts bladder cancer recurrence in Phase III